Example: Heart Attack

Clinical Trials Sponsored by Medicines for Malaria Venture

Total 83 results

NCT04368910

Terminated

Safety and Efficacy of Pyronaridine Artesunate Versus Chloroquine in Children and Adult Patients With Acute Plasmodium Vivax Malaria

Conditions: Malaria
NCT04310085

Completed

Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites

Conditions: Malaria,Falciparum; Parasitemia; Protozoan Infections; Parasitic Disease
NCT04456634

Completed

Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine

Conditions: Malaria
NCT04323306

Recruiting

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

Conditions: Malaria
NCT04069221

Completed

Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study

Conditions: Malaria
NCT03707041

Completed

Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model

Conditions: Malaria
NCT04002687

Completed

Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

Conditions: Malaria
NCT03637517

Completed

Malaria: Relative Bioavailability and Food Effect of DSM265

Conditions: Healthy Volunteers
NCT03542149

Completed

Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

Conditions: Malaria
NCT02450578

Completed

DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

Conditions: Plasmodium Falciparum, Malaria
NCT03195387

Withdrawn

Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model

Conditions: Malaria,Falciparum
NCT02885506

Completed

A FIH Study to Investigate the Safety, Tolerability and PK of P218

Conditions: Malaria
NCT02880241

Terminated

MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria

Conditions: Malaria
NCT02867059

Completed

SJ733 Induced Blood Stage Malaria Challenge Study

Conditions: Plasmodium Falciparum Malaria
NCT02783833

Completed

MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B

Conditions: Malaria
NCT02783820

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Conditions: Malaria
NCT02750384

Terminated

Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects

Conditions: Healthy Volunteers; Bioavailability
NCT02573857

Terminated

A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection

Conditions: Malaria
NCT02562872

Completed

DSM265 Prophylaxis of Plasmodium Falciparum Malaria

Conditions: Healthy
NCT02554799

Completed

A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers

Conditions: Malaria
NCT02453581

Completed

Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers

Conditions: Malaria
NCT02431650

Completed

Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent

Conditions: Malaria
NCT02431637

Completed

Experimental Falciparum Transmission to Anopheles

Conditions: Malaria
NCT01868438

Completed

Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations, in Healthy Volunteers

Conditions: Malaria
NCT02389348

Completed

A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265

Conditions: Malaria